After integrative analysis incorporating predicted and experimental candidates, the discovery of VEGFA, TP53, and HSPA8 in RO’s action on NPC treatments indicates novel targets for RO in treating NPC. This evidence concerns the gene TP53 and nasopharyngeal carcinoma.